14/03/2018 11:45:00

Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition

PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15 (Twirla®), an investigational, once-weekly, low-dose hormonal contraceptive patch, has been accepted as a poster presentation at the upcoming APhA 2018 (American Pharmacists Association) Annual Meeting & Exposition, which will be held from March 16 – 19, 2018 in Nashville, TN.

The poster will include a summary of efficacy and safety along with the results of the bleeding and wearability/tolerability profile from the SECURE study as previously reported. 

The presentation details are as follows:

Poster Title:  Results from the SECURE trial, a Phase 3 Study of the AG200-15 Investigational Transdermal Contraceptive Patch

Poster ID: 231

Room:  Exhibit Hall C-D, Music City Center

Date and Time: Saturday, March 17, 9:00am-6:00pm and Sunday, March 18, 9:00am-3:00pm

The Phase 3 SECURE study was a multicenter, single-arm, open-label, 13 cycle trial designed to evaluate the efficacy, safety and tolerability of AG200-15, also known as Twirla, in 2032 healthy women, aged 18 years and over, at 102 investigational sites across the United States. The SECURE study design included a number of stringent elements, including exclusion of treatment cycles for use of back-up contraception and for lack of sexual activity. The study also had broad entry criteria, placed no limitations on BMI or other demographic factors during enrollment, and enrolled a large and diverse patient population in order to allow efficacy to be assessed across different, real-world groups, as requested by the FDA. These entry criteria resulted in the inclusion of a substantial number of women with a high BMI, who have frequently been underrepresented in past contraceptive studies.

About Agile Therapeutics, Inc.

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla® (levonorgestrel/ethinyl estradiol transdermal system) or AG200-15, is a non-daily, prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin while optimizing patch adhesion and comfort for the patient.

For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company's website.  Follow Agile on LinkedIn and Twitter@AgileTher.

Forward-Looking Statement

Certain information contained in this press release includes "forward-looking statements" related to the Company's regulatory submissions. We may, in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," “designed,” "estimates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involves risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Our statements about the results of our clinical trial could be affected by the potential that there are changes in the interpretation of the data by the FDA (for example, the FDA continues to question the number of pregnancies included in our results and they may adjudicate additional pregnancies); our statements about the potential commercial opportunity could be affected by potential labeling restrictions, the potential that our product does not receive regulatory approval, does not receive reimbursement by third party payors, or a commercial market for the product does not develop because of any of the risks inherent in the commercialization of contraceptive products.  For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. All forward-looking statements are subject to risks detailed in our filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE:  Agile Therapeutics, Inc.

Investor Relations Contact:

Mary Coleman 

Agile Therapeutics

609-356-1921

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Jun
PNDORA
Carnegie´s senste negative udmeldning omkring en lille analyse foretaget blandt nogle franchisetager..
30
16 Jun
PNDORA
Som Pandora aktionær er jeg meget tilfreds med ledelsens indsats og de skabte resultater. Ledelsen l..
21
14 Jun
 
Jeg har et par gange øffet over niveauet herinde i dette debatforum. I første omgang skrev jeg til b..
18
18 Jun
PNDORA
              Jeg har lavet en fuld analyse på Pandora, som er en blanding af en regnskabs-analyse o..
17
16 Jun
VELO
Her er mit bud på begivenheder og dato for disse de næste 200 dage. Det bliver en god jul i år som i..
14
16 Jun
VWS
Nu er det jo Vestas der er mindst ramt af prispres, da de selv presser priser ned, da målet er at vi..
14
16 Jun
VWS
http://globenewswire.com/news-release/2018/06/15/1525456/0/en/Vestas-secures-442-MW-order-from-Xcel-..
13
14 Jun
VELO
Endnu et studie med Envarsus er startet op. Denne gang af Washington University School of Medicine. ..
13
19 Jun
VWS
https://www.vestas.com/en/media/company-news?n=1763161#!NewsView
12
14 Jun
PNDORA
Mange har snart mistet så mange penge på pandora, at de eneste smykker de har råd til at købe til ko..
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE
2
Publishing of Sponda's Half Year Financial Report January - June 2018
3
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
4
Swedish economy remains strong and budget surplus grows
5
BioSolar Signs a Joint Development Agreement with Ferroglobe, the Global Leader in the Supply of Silicon Material

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 June 2018 05:04:20
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-20 06:04:20 - 2018-06-20 05:04:20 - 1000 - Website: OKAY